Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccine Efficacy and Safety in Patients with Immune-Mediated Intestinal Diseases
share announcement

Vaccine Efficacy and Safety in Patients with Immune-Mediated Intestinal Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1187

Special Issue Editors

Dr. Adi Lahat

E-Mail
Guest Editor
Department of Gastroenterology, Chaim Sheba Medical Center, Affiliated to Tel Aviv University, Tel Aviv, Israel
Interests: gastroenterology; inflammatory bowel disease; diverticular disease; patient health; endoscopy; CRC screening
Special Issues, Collections and Topics in MDPI journals
Dr. Kassem Sharif

E-Mail Website
Guest Editor
Department of Gastroenterology, Chaim Sheba Medical Center, Affiliated to Tel Aviv University, Tel Aviv, Israel
Interests: gastroenterology; inflammatory bowel disease; celiac disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccination plays a crucial role in preventing infectious diseases and promoting public health. However, individuals with immune-mediated intestinal diseases, such as inflammatory bowel disease (IBD), celiac disease, and other related conditions, present unique challenges and considerations regarding vaccine efficacy and safety. These conditions are characterized by dysregulated immune responses, chronic inflammation, and the use of immunosuppressive therapies, which can potentially impact the immune response to vaccines and alter vaccine safety profiles. 

While vaccination is generally recommended for patients with immune-mediated intestinal diseases, there is a need for a comprehensive understanding of the specific factors influencing vaccine effectiveness and safety in this patient population. The dynamic interplay between the underlying disease pathophysiology, immune dysregulation, and immunosuppressive therapies complicates the assessment of vaccine responses and poses potential risks in terms of vaccine-related adverse events. 

This Special Issue aims to critically evaluate the current evidence regarding vaccine efficacy and safety in patients with immune-mediated intestinal diseases. It will explore the immune mechanisms underlying vaccine response alterations, the impact of immunosuppressive therapies on vaccine effectiveness, and the potential risks associated with vaccination in this population. Additionally, this Special Issue may discuss the available guidelines and recommendations for vaccination in patients with immune-mediated intestinal diseases, highlighting areas of uncertainty and areas that require further research. 

Understanding the specific challenges and considerations related to vaccine efficacy and safety in patients with immune-mediated intestinal diseases is essential for optimizing vaccination strategies in this vulnerable population. By shedding light on the current knowledge gaps and providing insights into potential solutions, this Special Issue aims to contribute to the development of evidence-based guidelines and recommendations for vaccination in patients with immune-mediated intestinal diseases. 

This Special Issue encourages the submission of original articles, systematic reviews, meta-analyses, short communications, and other types of articles that may seek to improve vaccination practices and promote the health and well-being of individuals with immune-mediated intestinal diseases while ensuring optimal protection against vaccine-preventable diseases and minimizing potential risks associated with vaccination.

Dr. Adi Lahat
Dr. Kassem Sharif
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease (IBD)
  • Crohn’s disease
  • ulcerative colitis
  • celiac disease
  • vaccines
  • immune-mediated intestinal disease

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1553 KiB  
Article
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
by Richard Vollenberg, Eva Ulla Lorentzen, Joachim Kühn, Tobias Max Nowacki, Jörn Arne Meier, Jonel Trebicka and Phil-Robin Tepasse
Vaccines 2023, 11(9), 1411; https://doi.org/10.3390/vaccines11091411 - 24 Aug 2023
Viewed by 953
Abstract
Introduction: The COVID-19 pandemic is a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccination against COVID-19 is crucial for preventing severe illness and controlling the pandemic. This study aimed to examine how immunosuppressed patients with inflammatory bowel disease (IBD) responded to [...] Read more.
Introduction: The COVID-19 pandemic is a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccination against COVID-19 is crucial for preventing severe illness and controlling the pandemic. This study aimed to examine how immunosuppressed patients with inflammatory bowel disease (IBD) responded to the third mRNA vaccination against SARS-CoV-2. The patients were undergoing treatments such as anti-TNF (infliximab, adalimumab), anti-α4ß7 integrin (vedolizumab), anti-IL12/23 (ustekinumab) and azathioprine (purine analog). Their responses were compared to those of healthy individuals. Methods: In this prospective study, 81 IBD patients and 15 healthy controls were enrolled 2–4 months after receiving the third mRNA vaccination. This study measured IgG antibody levels against the SARS-CoV-2 spike protein’s receptor binding domain (RBD) and assessed potential neutralization capacity using a surrogate virus neutralization test (sVNT). Results: Overall, immunosuppressed IBD patients (without SARS-CoV-2 infection) exhibited significantly lower levels of anti-S-IgG (anti-RBD-IgG) and binding inhibition in the sVNT after the third vaccination compared to healthy controls. Patients under anti-TNF therapy showed notably reduced anti-S-IgG levels after the booster vaccination, in contrast to those receiving ustekinumab and azathioprine (p = 0.030, p = 0.031). IBD patients on anti-TNF therapy demonstrated significantly increased anti-S-IgG levels following prior SARS-CoV-2 infection (p = 0.020). Conclusion: Even after the third vaccination, immunosuppressed IBD patients exhibited diminished humoral immunity compared to healthy controls, especially those on anti-TNF therapy. Cases of penetrating infections led to considerably higher antibody levels in IBD patients under anti-TNF therapy compared to uninfected patients. Further investigation through prospective studies in immunosuppressed IBD patients is needed to determine whether this effectively safeguards against future infections or severe disease. Full article
(This article belongs to the Special Issue Vaccine Efficacy and Safety in Patients with Immune-Mediated Intestinal Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop